Bone-marrow transplantation in non-malignant disease.

摘要

In haemopoietic stem-cell transplantation (HSCT), donor engraftment follows ablation of the recipient's marrow and immune system by conditioning chemoradiotherapy (before the transplantation) and by the alloimmune action (graft-versus-host marrow) of the engrafted donor cells against residual cells in the recipient. Thes.e processes are not always easy to control, and can lead to graft-versus-host disease (GVHD) when non-haemopoietic cells (eg, gut, skin, liver, and lung) are targeted. This outcome generates much risk of morbidity and mortality for the recipient. Therefore risk of transplantation is weighed against risk of disease in decision algorithms.